Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

5.55
+0.22004.13%
Post-market: 5.50-0.0489-0.88%19:30 EDT
Volume:234.69K
Turnover:1.28M
Market Cap:80.71M
PE:-1.56
High:5.55
Open:5.35
Low:5.18
Close:5.33
52wk High:11.89
52wk Low:3.16
Shares:14.54M
Float Shares:14.11M
Volume Ratio:1.67
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5600
EPS(LYR):-4.4408
ROE:-198.74%
ROA:-66.94%
PB:3.44
PE(LYR):-1.25

Loading ...

Company Profile

Company Name:
CINGULATE INC.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
14
Office Location:
1901 West 47th Place,Kansas City,Kansas,United States
Zip Code:
66205
Fax:
- -
Introduction:
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Directors

Name
Position
John A. Roberts
Chairman of the Board and Independent Director
Bryan Lawrence
Independent Director
Jeffrey S. Ervin
Independent Director
Zhanpeng Jiang
Independent Director
Peter J. Werth
Director

Shareholders

Name
Position
Shane J. Schaffer
Chief Executive Officer and Director
Jennifer L. Callahan
Executive Vice President, Chief Financial Officer & Secretary
Bryan Downey
Executive Vice President and Chief Commercial Officer
Matthew N. Brams
Executive Vice President and Chief Medical Officer
Nilay D. Patel
Executive Vice President, Chief Legal Officer & Chief Compliance Officer
Raul R. Silva
Executive Vice President and Chief Science Officer